Apr 28 2015
MagForce AG Installs Fifth NanoActivator(R) in Germany for the Treatment of Brain Tumors at Frankfurt University Hospital
MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the installation of the fifth NanoActivator(R). The device was installed at Frankfurt University Hospital to provide NanoTherm(TM) therapy for the treatment of brain cancers and the clinic will participate in MagForce's post marketing study. Since NanoTherm(TM) therapy has the European CE mark (in 27 EU countries), commercial patients can also be treated in Frankfurt. NanoActivator(R) devices are now available for treatment of patients with brain tumors at the University Medical Centers in Berlin, Münster, Kiel, Cologne, and Frankfurt.
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com
Source: http://www.magforce.com/